Subacute Necrotizing Encephalomyelopathy (Leigh Disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Subacute Necrotizing Encephalomyelopathy (Leigh Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Subacute Necrotizing Encephalomyelopathy also known as Leigh Disease is a severe neurological disorder. It is a genetically heterogeneous disease characterized by progressive loss of mental and movement abilities and ultimately death. mutations in mitochondrial respiratory chain complexes causes depletion in the production of ATP causing SNE. It is a rare form commonly occurring in infants. vomiting, diarrhea, and difficulty swallowing, growth retardation, muscle movement problems are common signs and symptoms. No standard diagnostic criteria for SNE but commonly detected by a wide range of laboratory, molecular, and radiographic findings. CBP picture, CSF analysis, MI and chest X-ray are done. No standard therapy for SNE but symptomatic therapy is provided to treat acidosis with sodium bicarbonate, if seizures seen anti-epileptic medications, and nutraceutical support.
The Subacute Necrotizing Encephalomyelopathy (Leigh Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Subacute Necrotizing Encephalomyelopathy (Leigh Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Subacute Necrotizing Encephalomyelopathy (Leigh Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Subacute Necrotizing Encephalomyelopathy (Leigh Disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 15 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Subacute Necrotizing Encephalomyelopathy (Leigh Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Subacute Necrotizing Encephalomyelopathy (Leigh Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Subacute Necrotizing Encephalomyelopathy (Leigh Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abliva ABAutonomous University of Barcelona
CAMP Therapeutics Inc
Charite University Medicine Berlin
Imbria Pharmaceuticals Inc
Ixchel Pharma LLC
Khondrion BV
Minovia Therapeutics Ltd
Myto Therapeutics Inc
Neurocores Inc
PTC Therapeutics Inc
Stealth BioTherapeutics Inc.
Taysha Gene Therapies Inc
Unravel Biosciences
Table of Contents
Table
Figures
Frequently asked questions